The Front Office

Scouting report · CAI

Luke Power

  • SVP, Chief Financial Officer & Chief Accounting Officer, CAI since 2023-02src

Joined Caris in 2011 as an accounting manager; CFO since February 2023

—thin record

Not ranked yet

Scouting sheet

as of 24 Sep 2026
Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design—no proxy read yet
Skin in the game—no holding or price on file
Age
44src
In the role
4 yr
Promises scored
0
Hit rate
—
Dodges / 100 answers
—
Airtime on calls
—
Every promise, oldest firstno scored promises yet

What to weigh

Red flag 1

  • Disclosure controls were not effective at 2026-06-30. A material weakness (too few qualified accounting staff for complex transactions), found in the FY2024 audit, is still being remediated, and he is both CFO and CAOsrc

Watch 3

  • An earlier material weakness (several control deficiencies in applying GAAP) was reported for FY2022-FY2023 while he was CAO. EY then declined to stand for the 2024 audit, and Deloitte was engaged in September 2024src
  • His pay is not disclosed. He was not a named executive officer in the 2026 proxy or the IPO prospectus, and as an emerging growth company Caris reports only three NEOssrc
  • On 2025-12-11 he exercised 62,250 options at $2.44 and sold 62,250 shares for about $1.65m under a 10b5-1 plan adopted 2025-08-19. Afterwards he held 99,571 shares, which were the 250 shares on his IPO Form 3 plus the 99,321 IPO RSUssrc

Career

  1. 2023-02 – now
    Caris Life Sciencessrc
    SVP, Chief Financial Officer & Chief Accounting Officer
    CFO through the April 2025 crossover financing and the June 2025 IPO
  2. 2017-04 – 2023-02
    Caris Life Sciencessrc
    Chief Accounting Officer
  3. 2016-05 – 2016-09
    Caris Life Sciencessrc
    Senior Director of Accounting
  4. 2013-08 – 2016-05
    Caris Life Sciencessrc
    Director of Accounting
  5. 2011-12 – 2013-08
    Caris Life Sciencessrc
    Financial Reporting and Accounting Manager
    Joining role; the filing does not give its end date, which is taken as the start of the next role
  6. 2002-11 – 2011-10
    PricewaterhouseCooperssrc
    Manager, international assurance practice
    The Caris bio adds that he worked in PwC's assurance practice in Ireland, the United States and the United Kingdom (WS-bio)

Not located: 2016-09 to 2017-04: the 10-K and the IPO prospectus give him no title between Senior Director of Accounting and Chief Accounting Officer

Achievements

  • Spent twelve years moving up Caris's finance function, from accounting manager (2011) to Chief Accounting Officer (2017) to CFO (2023)src
  • Was CFO and principal accounting officer through the April 2025 crossover financing and the June 2025 IPOsrc
  • Certified public accountant and Fellow of Chartered Accountants Ireland, after nine years in PwC's assurance practicesrc

Education

  • Waterford Institute of Technology, Degree Finance and accountingsrc

Background

  • Family The 2026 proxy names only one family relationship among directors and executive officers, the Halbert brothers. None involves himsrc
  • Other Caris native: every job in the ten-year window is at Caris. He has no public-company CFO role elsewheresrc
  • Other Named with the CEO and General Counsel as a proxy holder for the 2026 annual meeting, and signed the meeting's 8-Ksrc

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Sources

9
  1. Filing Caris Life Sciences 10-K for FY2025, Information about our Executive Officers (0002019410-26-000016) · 2026-03-03
  2. Filing Caris Life Sciences DEF 14A (accession 0002019410-26-000032) · 2026-04-23
  3. Filing Caris Life Sciences IPO prospectus, 424B4 (0001104659-25-060762) · 2025-06-20
  4. Filing Caris Life Sciences 10-Q for the quarter ended 2026-06-30 (0002019410-26-000055) · 2026-08-05
  5. Filing Form 3, Luke Thomas Power (reporting CIK 2072013), at the IPO (0001104659-25-060384) · 2025-06-17
  6. Filing Form 4, Luke Thomas Power, option exercise and 10b5-1 sale of 2025-12-11 (0002072013-25-000006) · 2025-12-12
  7. Filing Form 4, Luke Thomas Power, RSU grant of 2026-03-06 (0002072013-26-000002) · 2026-03-10
  8. Filing Form 4, Luke Thomas Power, tax withholding on RSU vesting of 2026-05-15 (0002072013-26-000004) · 2026-05-18
  9. Web search result WebSearch: Luke Power Caris Life Sciences CFO Waterford (result summary drawing on the Caris bio page) · 2026-09-24